Lumenis Presented VersaPulse™ Holmium Lasers at 30th World Congress of Endourology

Share Article

HoLEP Simulation Wet Lab to Treat Prostate Models Featured

News Image
The versatility of these high end products enables superior clinical outcome for a wide range of conditions, from stones of all types to Benign Prostatic Hyperplasia (BPH) and other soft tissue applications.

Lumenis Ltd., the world's largest medical laser company which develops, manufactures and distributes a broad range of medical lasers and sophisticated energy delivery equipment for surgical, aesthetic and ophthalmic applications, announces its participation at the 30th World Congress of Endourology (WCE) and SWL held in Istanbul, Turkey on September 4-8th, 2012.

Lumenis’ VersaPulse™ holmium lasers were showcased at the show. The versatility of these high end products enables superior clinical outcome for a wide range of conditions, from stones of all types to Benign Prostatic Hyperplasia (BPH) and other soft tissue applications.

  •     VersaPulse PowerSuite™ Holmium Laser –. The VersaPulse PowerSuite family of Holmium and Dual Wavelength lasers offers a variety of systems and fibers to meet Urology’s varying clinical needs in both an office and hospital setting.
  •     VersaPulse PowerSuite™ 100W - Although best known for treating urologic applications such as BPH, stones, tumors or strictures, VersaPulse 100W is also FDA cleared to treat a range of applications in other surgical fields, making it a versatile and economic choice.
  •     VersaPulse P20 – The VersaPulse P20 is a leading, affordable and portable laser for treating all types of stones. This laser suits all sizes, composition and location of stones and allows for reduced procedure time for stone dusting procedures.

At the booth, Lumenis ran a HoLEP Wet Lab with Lumenis lasers. Physicians participated in hands-on simulated HoLEP procedures used to treat BPH.

“Lumenis has consistently made a positive impact in the treatment of HoLEP using our VersaPulse holmium solutions. Leading physicians who have been trained on our technology and who have honed their skills thereafter have brought recognition to the HoLEP procedure as a best treatment choice for BPH for patients,” said Danny Albeck, Lumenis’ VP of Research & Development and Acting VP of the Surgical Division.
For more information on UltraPulse, contact Lumenis or visit http://www.lumenis.com

About Lumenis

Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, aesthetic and ophthalmic applications, with more than 900 employees worldwide. Lumenis has 265 registered patents, over 260 FDA clearances, an installed base of over 80,000 systems and a presence in over 80 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning ”Light of Life” highlighting the light - the basis of our technologies - used to enhance life. For more information about Lumenis and its products, please visit: http://www.lumenis.com.

For further information contact:

Julie Shafiki
Director, Global Marketing Communications
+972-4-959-9113
e-mail: julie.shafiki(at)lumenis(dot)com

Lumenis® and the Lumenis logo are trademarks or registered trademarks of Lumenis.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Julie Shafiki
Lumenis LTD
+972-544991970
Email >
Visit website